在使用Baloxavir Marboxil后出现了缺血性结肠炎病例
1Department of Endoscopy, Tanaka Clinic, Japan.
Internal medicine (Tokyo, Japan)
|September 3, 2025
概括
作为A型流感的治疗药物,巴洛克萨维尔可导致缺血性结肠炎. 一个病例研究发现患者服用药物后出现大肠炎症状,突出显示了潜在的不良事件.
科学领域:
- 胃肠病学
- 传染性疾病
- 药理学
背景情况:
- A型流感是一种常见的呼吸道疾病.
- 巴洛克萨维尔马博西尔是一种用于治疗甲型流感的抗病毒药物.
- 任何药物都可能产生不良反应.
研究的目的:
- 报告可能与巴洛克萨维尔马博西尔相关的缺血性结肠炎病例.
- 提高临床医生对这种可能的不良事件的认识.
主要方法:
- 一个60多岁的妇女用巴洛克萨维尔治疗A型流感的病例报告.
- 记录了临床表现,结肠镜检查结果和组织病理学检查.
- 记录了患者的治疗方法和结果.
主要成果:
- 在服用巴洛克萨维尔马博西尔两天后,患者出现腹痛,腹和血.
- 结肠镜检测出结肠粘膜和纵向.
- 细胞病理学证实了缺血性大肠炎.
- 经过保守的治疗,症状有所改善.
结论:
- 缺血性结肠炎是与巴洛克萨维尔马博西尔相关的一种潜在不良反应.
- 临床医生应考虑在服用药物后出现胃肠道症状的患者.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
236
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
236
Inflammatory Bowel Disease I: Ulcerative Colitis
316
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
316
Drugs for Treatment of Diarrhea-Predominant IBS
292
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
292
Inflammatory Bowel Disease IV: Pharmacological Management
185
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
185
Chronic Bowel Disorders: Introduction
540
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
540
Drugs for Treatment of Constipation-Predominant IBS
326
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
326


